Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Mayer, R; Pummer, K; Quehenberger, F; Mayer, E; Fink, L; Hackl, A.
Postprostatectomy radiotherapy for high-risk prostate cancer.
Urology. 2002; 59(5):732-739
Doi: 10.1016%2FS0090-4295%2802%2901502-9
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Mayer Ramona
- Co-Autor*innen der Med Uni Graz
- Hackl Arnulf
- Mayer Elisabeth
- Pummer Karl
- Quehenberger Franz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVES: To assess the biochemical and clinical results of postprostatectomy radiotherapy (RT) for high-risk, mostly non-rgan-confined prostate cancer. METHODS: After radical prostatectomy, 66 consecutive patients received either adjuvant (n = 29) or therapeutic (n = 37) postoperative RT. Therapeutic RT was given for persistently elevated postoperative prostate-specific antigen (PSA) levels (n = 14), gradually rising PSA levels (n = 6), or clinical local recurrence (n = 17). The selection of time and referral for RT was at the discretion of the treating urologists. RESULTS: The mean and median follow-up after surgery was 56.8 and 54.2 months, and after radiotherapy, it was 43.2 and 35.0 months, respectively. At 5 years, the actuarial biochemical control for the whole collective was 59.7% (95% confidence interval [CI] 43.3% to 72.8%). Patients treated with adjuvant RT had statistically improved biochemical control (85.2% versus 34.0%, P = 0.001), but not disease-free survival (91% versus 73%, P = 0.09). Advanced tumor stage (pT3b-4) (relative risk 16.6; 95% CI 0.9 to 313.3; P = 0.01), poorly differentiated histologic features (relative risk 4.63; 95% CI 1.8 to 12.2; P = 0.001), and pre-RT PSA (relative risk 1.15, 95% CI 1.06 to 1.25; P = 0.003) were associated with a statistically significant increased risk of biochemical failure. CONCLUSIONS: Although adjuvant postoperative RT resulted in improved biochemical control, no significant difference in disease-free survival has been obtained to date. It therefore remains to be determined whether the better biochemical control observed will ultimately translate into a survival benefit after longer follow-up and prospective trials.
- Find related publications in this database (using NLM MeSH Indexing)
- Confidence Intervals -
- Disease-Free Survival -
- Follow-Up Studies -
- Humans -
- Male -
- Middle Aged -
- Neoplasm Recurrence, Local - blood
- Prostate-Specific Antigen - blood
- Prostatectomy - blood
- Prostatic Neoplasms - blood
- Radiotherapy, Adjuvant - blood